Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Anticancer Res ; 30(12): 5049-54, 2010 Dec.
Article de Anglais | MEDLINE | ID: mdl-21187489

RÉSUMÉ

Experimental and clinical data indicated that perioperative administration of the hemostatic peptide desmopressin (DDAVP) can inhibit progression of residual metastatic cells. The compound seems to act by inducing an agonist effect on specific V2 vasopressin membrane receptors present in both tumor cells and endothelial cells. Here we explored the antitumor effects of DDAVP in cultured colon carcinoma cells and in a syngeneic Balb/c mouse model. Both human Colo-205 and mouse CT-26 colon carcinoma cell lines expressed the V2 receptor, as revealed by immunofluorescence. DDAVP (at doses ranging from 100 ng/ml to 1 µg/ml) exerted a modest but significant antiproliferative effect on cultured CT-26 and Colo-205 cells. In vivo, DDAVP (2 intravenous doses of 2 µg/kg) reduced accumulation of ascites and formation of intestinal tumor nodules in mice intraperitoneally inoculated with CT-26 cells. Perioperative administration of DDAVP significantly inhibited tumor progression in animals surgically implanted in the spleen with CT-26 cells, and caused some reduction in liver metastasis. Although DDAVP and 5-fluorouracil demonstrated additive cytostatic effects in vitro, no antitumor effects were observed in this study in mice receiving a single cycle of chemotherapy (25 mg/kg) in combination with the peptide. Our data suggest that DDAVP may be potentially used to minimize spread or survival of residual malignant cells during surgical procedures for colon and other gastrointestinal tumors.


Sujet(s)
Tumeurs du côlon/traitement médicamenteux , Desmopressine/pharmacologie , Animaux , Antinéoplasiques/pharmacologie , Lignée cellulaire tumorale , Tumeurs du côlon/métabolisme , Technique d'immunofluorescence , Humains , Mâle , Souris , Souris de lignée BALB C , Récepteurs à la vasopressine/biosynthèse
2.
Biochem Biophys Res Commun ; 289(2): 325-8, 2001 Nov 30.
Article de Anglais | MEDLINE | ID: mdl-11716475

RÉSUMÉ

We investigated the targeting of the V(1a) receptor fused with the green fluorescence protein (V(1a)R-GFP) in polarized MDCK cells. Cells expressing V(1a)R-GFP displayed binding to vasopressin (AVP) and AVP-induced calcium responses, similar to cells expressing the wild-type V1a receptor. Interestingly, as with the wild-type V(1a)R, V(1a)R-GFP is preferentially distributed in the basolateral side of MDCK cells as monitored by confocal microscopy. Furthermore, AVP induced internalization of GFP-tagged receptors. Therefore, the GFP-tagged V(1a) receptor retains all the sorting signals of the wild-type receptor and offers an excellent system to elucidate the mechanisms of cell trafficking of V(1a) receptors.


Sujet(s)
Protéines luminescentes/métabolisme , Récepteurs à la vasopressine/biosynthèse , Récepteurs à la vasopressine/composition chimique , Protéines de fusion recombinantes/métabolisme , Animaux , Calcium/métabolisme , Lignée cellulaire , ADN complémentaire/métabolisme , Chiens , Relation dose-effet des médicaments , Vecteurs génétiques , Protéines à fluorescence verte , Cinétique , Foie/métabolisme , Microscopie confocale , Liaison aux protéines , Rats , RT-PCR , Facteurs temps , Transfection
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE